1. Home
  2. companies
  3. JNJ

JNJ

Johnson & Johnson ordered to pay $5.6 mln in California mesh trial
Johnson & Johnson ordered to pay $5.6 mln in California mesh trial
Yahoo/Reuters
JNJ
pelvic mesh
Ethicon
Inside the $21 Billion War for a Blockbuster Cancer Drug
Inside the $21 Billion War for a Blockbuster Cancer Drug
Yahoo/Bloomberg
AbbVie
Pharmacyclics
M&A
Imbruvica
JNJ
J&J Said to Agree to Acquire Pharmacyclics for Cancer Drug
J&J Said to Agree to Acquire Pharmacyclics for Cancer Drug
Bloomberg
JNJ
M&A
Pharmacyclics
Imbruvica
Merck touts a bright future in biosimilars with a stable of would-be blockbusters
Merck touts a bright future in biosimilars with a stable of would-be blockbusters
Fierce Biotech
Merck
biosimilars
AbbVie
Humira
JNJ
Remicade
Amgen
Enbrel
Samsung Bioepis
Biogen Idec
Will Medivation Kick J&J To The Curb For This $9 Billion Market?
Will Medivation Kick J&J To The Curb For This $9 Billion Market?
Seeking Alpha
JNJ
Medivation
Xtandi
J&J picks the inaugural class for its Bay Area biotech incubator
J&J picks the inaugural class for its Bay Area biotech incubator
Fierce Biotech
JNJ
biotech
JLabs
Johnson & Johnson Announces Binding Offer from Cardinal Health to Acquire Cordis
Johnson & Johnson Announces Binding Offer from Cardinal Health to Acquire Cordis
Yahoo
JNJ
Cardinal Health
Cordis
M&A
Who Might Buy Puma Biotechnology?
Who Might Buy Puma Biotechnology?
Barron's
Puma Biotechnology
M&A
Gilead Sciences
JNJ
Sanofi
FDA postpones key hearing on biosimilar copy of blockbuster drug
FDA postpones key hearing on biosimilar copy of blockbuster drug
Yahoo/Reuters
FDA
biosimilars
Rensima
Remicade
JNJ
rheumatoid arthritis
Crohn's Disease
Hospira
Celltrion
South Carolina court orders J&J to pay $136 mln in Risperdal case
South Carolina court orders J&J to pay $136 mln in Risperdal case
Yahoo/Reuters
South Carolina
JNJ
Risperdal
Pharmacyclics mulls sale; J&J, Novartis interested - Bloomberg
Pharmacyclics mulls sale; J&J, Novartis interested - Bloomberg
Yahoo/Reuters
Pharmacyclics
JNJ
Novartis
M&A
Johnson & Johnson Loses Trial Over Risperdal And Male Breasts
Johnson & Johnson Loses Trial Over Risperdal And Male Breasts
WSJ/Pharmalot
JNJ
Risperdal
lawsuits
J&J Hid Risperdal Risks of Male Breast Development, Jury Told
J&J Hid Risperdal Risks of Male Breast Development, Jury Told
Bloomberg
JNJ
Risperdal
Johnson & Johnson reportedly in talks to sell its Cordis unit; Cardinal Health is rumored to be the leading bidder
Johnson & Johnson reportedly in talks to sell its Cordis unit; Cardinal Health is rumored to be the leading bidder
Bidness Etc.
JNJ
Cordis
devices
M&A
Cardinal Health
Will Boston Scientific Corporation (BSX) Learn From Its Guidant Mishap?
Will Boston Scientific Corporation (BSX) Learn From Its Guidant Mishap?
Bidness Etc.
Boston Scientific
Guidant
JNJ
devices
Boston Scientific to pay J&J $600 million to settle Guidant suit
Boston Scientific to pay J&J $600 million to settle Guidant suit
Mass Device
Boston Scientific
devices
JNJ
Guidant
Pelvic Mesh lawsuits: J&J drops claim that women were asked to lie for payouts
Pelvic Mesh lawsuits: J&J drops claim that women were asked to lie for payouts
Mass Device
JNJ
pelvic mesh
devices
J&J-Pharmacyclics drug shows potential in high-risk leukemia patients
J&J-Pharmacyclics drug shows potential in high-risk leukemia patients
Yahoo/Reuters
JNJ
Pharmacyclics
Imbruvica
chronic lymphocytic leukemia
FirstWord Lists – The best selling drugs in 2014
FirstWord Lists – The best selling drugs in 2014
First Word Pharma
Humira
Sovaldi
Remicade
Enbrel
Lantus
Rituxan
Advair
Avastin
Herceptin
Januvia
Merck
AbbVie
Gilead Sciences
JNJ
Amgen
Pfizer
Sanofi
Roche
GSK
Johnson & Johnson aim to spot who'll get a disease
Johnson & Johnson aim to spot who'll get a disease
The News Star
JNJ

Click here to subscribe to daily news headlines in your email inbox